Mira Pharmaceuticals Inc. recently announced progress in its regulatory endeavors, as the acquisition of SKNY Pharmaceuticals is advancing as planned. The company has successfully submitted the necessary regulatory filings for the merger to the U.S. Securities and Exchange Commission $(SEC.UK)$. This acquisition includes SKNY Pharmaceuticals' first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation, SKNY-1. Furthermore, Mira Pharmaceuticals is on track to initiate a Phase 2a trial for Ketamir-2 in neuropathic pain by year-end 2025, pending regulatory clearance. This development marks a significant step in Mira Pharmaceuticals' clinical pipeline expansion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.